<!DOCTYPE html>
<html lang="en">
	<head>
		<meta charset="UTF-8" />
		<meta http-equiv="X-UA-Compatible" content="IE=edge" />
		<meta name="viewport" content="width=device-width, initial-scale=1.0" />
		<title>Document</title>
		<link rel="stylesheet" href="../icons/css/fontawesome.css" />
		<link rel="stylesheet" href="../icons/css/solid.css" />
		<link rel="stylesheet" href="../icons/css/regular.css" />
		<link rel="stylesheet" href="../icons/css/brands.css" />
		<link rel="stylesheet" href="../icons/css/light.css" />
		<link rel="stylesheet" href="../css/styleguide_override.css" />
		<link
			rel="stylesheet"
			href="//fonts.googleapis.com/css?family=Roboto+Slab&amp;display=swap"
		/>
		<link
			rel="stylesheet"
			href="//fonts.googleapis.com/css?family=Muli&amp;display=swap"
		/>
		<link
			rel="stylesheet"
			href="//fonts.googleapis.com/css?family=OpenSans&amp;display=swap"
		/>
		<link rel="stylesheet" href="../css/color-code_social.css" />
		<link rel="stylesheet" href="../css/color-code_LOE_COR.css" />
		<link rel="stylesheet" href="../css/acc_uc.min.css" />
		<link rel="stylesheet" href="../css/glsearch.min.css" />
	</head>
	<body>
		<div class="swg-result">
			<section id="hl0005480">
				<a id="sec10"></a>
				<section id="hl0007506">
					<a id="sec10.9"></a>
					<section id="hl0007580">
						<a id="sec10.9.1"></a>
						<section id="hl0007917">
							<a id="sec10.9.1.3"></a><a id="sectitle0450"></a>
							<h3 id="hl0007919">
								<span class="section-label">7.9.1.3</span
								>&nbsp;Brugada Syndrome
							</h3>
							<div id="undtbl35" class="table">
								<div class="inline-table-caption">
									Recommendations for Brugada Syndrome
								</div>
								<div class="inline-table-caption">
									References that support the recommendations
									are summarized in
									<a
										id="hl0007926"
										href="http://jaccjacc.acc.org/Clinical_Document/2017_VASCD_Data_Supplement.pdf"
										target="_blank"
										>Online Data Supplement 42</a
									>
									and Systematic Review Report.
								</div>
								<div>
									<table id="hl0007927">
										<thead>
											<tr>
												<th
													id="hl0007933"
													scope="col"
													class="table-align-"
												>
													COR
												</th>
												<th
													id="hl0007934"
													scope="col"
													class="table-align-"
												>
													LOE
												</th>
												<th
													id="hl0007935"
													scope="col"
													class="table-align-"
												>
													Recommendations
												</th>
											</tr>
										</thead>
										<tbody>
											<tr>
												<td
													id="hl0007938"
													class="table-align-"
												>
													<b>I</b>
												</td>
												<td
													id="hl0007940"
													class="table-align-"
												>
													<b>B-NR</b>
												</td>
												<td
													id="hl0007942"
													class="table-align-"
												>
													<ul id="hl0007943">
														<li id="hl0007944">
															<span
																class="list-item-label"
															></span>
															<p id="hl0007947">
																<b
																	>In
																	asymptomatic
																	patients
																	with only
																	inducible
																	type 1
																	Brugada
																	electrocardiographic
																	pattern,
																	observation
																	without
																	therapy is
																	recommended.</b
																>
															</p>
														</li>
													</ul>
												</td>
											</tr>
											<tr>
												<td
													id="hl0007950"
													class="table-align-"
												>
													<b>I</b>
												</td>
												<td
													id="hl0007952"
													class="table-align-"
												>
													<b>B-NR</b>
												</td>
												<td
													id="hl0007954"
													class="table-align-"
												>
													<ul id="hl0007955">
														<li id="hl0007956">
															<span
																class="list-item-label"
															></span>
															<p id="hl0007959">
																<b
																	>In patients
																	with Brugada
																	syndrome
																	with
																	spontaneous
																	type 1
																	Brugada
																	electrocardiographic
																	pattern and
																	cardiac
																	arrest,
																	sustained VA
																	or a recent
																	history of
																	syncope
																	presumed due
																	to VA, an
																	ICD is
																	recommended
																	if
																	meaningful
																	survival of
																	greater than
																	1 year is
																	expected</b
																><a
																	class="inline-reference"
																	href="#bib856"
																	><b
																		>[1]</b
																	></a
																>,&nbsp;<a
																	class="inline-reference"
																	href="#bib858"
																	><b
																		>[2]</b
																	></a
																><b>.</b>
															</p>
														</li>
													</ul>
												</td>
											</tr>
											<tr>
												<td
													id="hl0007965"
													class="table-align-"
												>
													<b>I</b>
												</td>
												<td
													id="hl0007967"
													class="table-align-"
												>
													<b>B-NR</b>
												</td>
												<td
													id="hl0007969"
													class="table-align-"
												>
													<ul id="hl0007970">
														<li id="hl0007971">
															<span
																class="list-item-label"
															></span>
															<p id="hl0007974">
																<b
																	>In patients
																	with Brugada
																	syndrome
																	experiencing
																	recurrent
																	ICD shocks
																	for
																	polymorphic
																	VT,
																	intensification
																	of therapy
																	with
																	quinidine or
																	catheter
																	ablation is
																	recommended</b
																><a
																	class="inline-reference"
																	href="#bib859"
																	><b
																		>[1]</b
																	></a
																>,&nbsp;<a
																	class="inline-reference"
																	href="#bib860"
																	><b
																		>[2]</b
																	></a
																>,&nbsp;<a
																	class="inline-reference"
																	href="#bib861"
																	><b
																		>[3]</b
																	></a
																>,&nbsp;<a
																	class="inline-reference"
																	href="#bib862"
																	><b
																		>[4]</b
																	></a
																>,&nbsp;<a
																	class="inline-reference"
																	href="#bib863"
																	><b
																		>[5]</b
																	></a
																><b>.</b>
															</p>
														</li>
													</ul>
												</td>
											</tr>
											<tr>
												<td
													id="hl0007980"
													class="table-align-"
												>
													<b>I</b>
												</td>
												<td
													id="hl0007982"
													class="table-align-"
												>
													<b>B-NR</b>
												</td>
												<td
													id="hl0007984"
													class="table-align-"
												>
													<ul id="hl0007985">
														<li id="hl0007986">
															<span
																class="list-item-label"
															></span>
															<p id="hl0007989">
																<b
																	>In patients
																	with
																	spontaneous
																	type 1
																	Brugada
																	electrocardiographic
																	pattern and
																	symptomatic
																	VA who
																	either are
																	not
																	candidates
																	for or
																	decline an
																	ICD,
																	quinidine or
																	catheter
																	ablation is
																	recommended</b
																><a
																	class="inline-reference"
																	href="#bib859"
																	><b
																		>[1]</b
																	></a
																>,&nbsp;<a
																	class="inline-reference"
																	href="#bib861"
																	><b
																		>[2]</b
																	></a
																>,&nbsp;<a
																	class="inline-reference"
																	href="#bib862"
																	><b
																		>[3]</b
																	></a
																>,&nbsp;<a
																	class="inline-reference"
																	href="#bib863"
																	><b
																		>[4]</b
																	></a
																><b>.</b>
															</p>
														</li>
													</ul>
												</td>
											</tr>
											<tr>
												<td
													id="hl0007995"
													class="table-align-"
												>
													<b>IIa</b>
												</td>
												<td
													id="hl0007997"
													class="table-align-"
												>
													<b>B-NR</b>
												</td>
												<td
													id="hl0007999"
													class="table-align-"
												>
													<ul id="hl0008000">
														<li id="hl0008001">
															<span
																class="list-item-label"
															></span>
															<p id="hl0008004">
																<b
																	>In patients
																	with
																	suspected
																	Brugada
																	syndrome in
																	the absence
																	of a
																	spontaneous
																	type 1
																	Brugada
																	electrocardiographic
																	pattern, a
																	pharmacological
																	challenge
																	using a
																	sodium
																	channel
																	blocker can
																	be useful
																	for
																	diagnosis</b
																><a
																	class="inline-reference"
																	href="#bib864"
																	><b
																		>[1]</b
																	></a
																>,&nbsp;<a
																	class="inline-reference"
																	href="#bib865"
																	><b
																		>[2]</b
																	></a
																>,&nbsp;<a
																	class="inline-reference"
																	href="#bib866"
																	><b
																		>[3]</b
																	></a
																><b>.</b>
															</p>
														</li>
													</ul>
												</td>
											</tr>
											<tr>
												<td
													id="hl0008010"
													class="table-align-"
												>
													<b>IIb</b>
												</td>
												<td
													id="hl0008012"
													class="table-align-"
												>
													<b>B-NR</b><sup>SR</sup>
												</td>
												<td
													id="hl0008015"
													class="table-align-"
												>
													<ul id="hl0008016">
														<li id="hl0008017">
															<span
																class="list-item-label"
															></span>
															<p id="hl0008020">
																<b
																	>In patients
																	with
																	asymptomatic
																	Brugada
																	syndrome and
																	a
																	spontaneous
																	type 1
																	Brugada
																	electrocardiographic
																	pattern, an
																	electrophysiological
																	study with
																	programmed
																	ventricular
																	stimulation
																	using single
																	and double
																	extrastimuli
																	may be
																	considered
																	for further
																	risk
																	stratification</b
																><a
																	class="inline-reference"
																	href="#bib853"
																	><b
																		>[1]</b
																	></a
																>,&nbsp;<a
																	class="inline-reference"
																	href="#bib858"
																	><b
																		>[2]</b
																	></a
																>,&nbsp;<a
																	class="inline-reference"
																	href="#bib865"
																	><b
																		>[3]</b
																	></a
																>,&nbsp;<a
																	class="inline-reference"
																	href="#bib867"
																	><b
																		>[4]</b
																	></a
																>,&nbsp;<a
																	class="inline-reference"
																	href="#bib868"
																	><b
																		>[5]</b
																	></a
																>,&nbsp;<a
																	class="inline-reference"
																	href="#bib869"
																	><b
																		>[6]</b
																	></a
																><b>.</b>
															</p>
														</li>
													</ul>
												</td>
											</tr>
											<tr>
												<td
													id="hl0008026"
													class="table-align-"
												>
													<b>IIb</b>
												</td>
												<td
													id="hl0008028"
													class="table-align-"
												>
													<b>C-EO</b>
												</td>
												<td
													id="hl0008030"
													class="table-align-"
												>
													<ul id="hl0008031">
														<li id="hl0008032">
															<span
																class="list-item-label"
															></span>
															<p id="hl0008035">
																<b
																	>In patients
																	with
																	suspected or
																	established
																	Brugada
																	syndrome,
																	genetic
																	counseling
																	and genetic
																	testing may
																	be useful to
																	facilitate
																	cascade
																	screening of
																	relatives</b
																><a
																	class="inline-reference"
																	href="#bib870"
																	><b
																		>[1]</b
																	></a
																>,&nbsp;<a
																	class="inline-reference"
																	href="#bib871"
																	><b
																		>[2]</b
																	></a
																>,&nbsp;<a
																	class="inline-reference"
																	href="#bib872"
																	><b
																		>[3]</b
																	></a
																><b>.</b>
															</p>
														</li>
													</ul>
												</td>
											</tr>
										</tbody>
									</table>
								</div>
								<div class="inline-table-caption">
									SR indicated systematic review.
								</div>
							</div>
							<p id="hl0008042"><i>and</i>.</p>
							<div class="inline-image figure" id="fig14">
								<figure>
									<figcaption class="inline-image-label">
										Figure 14
									</figcaption>
									<img
										src="https://d1niluoi1dd30v.cloudfront.net/07351097/S0735109717X00442/S0735109717413064/gr14-t.gif?Expires=1621437001&Signature=bEY9rAfWoE553OVb1rFXGbJxHkZBZKl001L5QnooBlkwuEjEARIW9MqZCU8MkU~~m5rM6LPl3IiXnwG33V-7bEwpCSXodgIWSmUld-Ox5GWyT99shdvmAUvCaatUzd2rLUVrSNeE82wt7lYciVYlGAGbs1cWN~YQjMI~iNkz6oc_&Key-Pair-Id=APKAICLNFGBCWWYGVIZQ"
										alt=""
										data-eid="1-s2.0-S0735109717413064"
										data-locator="gr14"
										data-attachment-filename="07351097/S0735109717X00442/S0735109717413064/gr14-t.gif"
									/>
									<div class="caption-holder">
										<div class="inline-image-caption">
											Prevention of SCD in Patients With
											Brugada Syndrome
										</div>
										<div class="inline-image-caption">
											Colors correspond to Class of
											Recommendation in . See for
											discussion. *ICD candidacy as
											determined by functional status,
											life expectancy or patient
											preference. 1° indicates primary;
											ECG, electrocardiogram; EP,
											electrophysiological; ICD
											implantable
											cardioverter-defibrillator; SCD,
											sudden cardiac death; VT,
											ventricular tachycardia; and VF,
											ventricular fibrillation.
										</div>
									</div>
								</figure>
							</div>
							<div class="inline-image figure" id="fig15">
								<figure>
									<figcaption class="inline-image-label">
										Figure 15
									</figcaption>
									<img
										src="//"
										alt=""
										data-eid="1-s2.0-S0735109717413064"
										data-locator="gr15"
										data-attachment-filename="07351097/S0735109717X00442/S0735109717413064/gr15-t.gif"
									/>
									<div class="caption-holder">
										<div class="inline-image-caption">
											Brugada Syndrome
										</div>
									</div>
								</figure>
							</div>
							<p id="hl0008050"><b>Synopsis</b></p>
							<p id="hl0008052">
								Refer to the “Systematic Review for the 2017
								ACC/AHA/HRS Guideline for Management of Patients
								With Ventricular Arrhythmias and the Prevention
								of Sudden Cardiac Death” for the complete
								systematic evidence review for additional data
								and analyses
								<a class="inline-reference" href="#bib867"
									>(S7.9.1.3-15)</a
								>. The results from the question “For
								asymptomatic patients with Brugada syndrome,
								what is the association between an abnormal EP
								study and SCD and other arrhythmia endpoints?
								(Part 1)” and the writing committee’s review of
								the totality of the literature were used to
								frame decision-making. Recommendations that are
								based on a body of evidence that includes the
								systematic review conducted by the ERC are
								denoted by the superscript SR (e.g., LOE: B-R
								<sup>SR</sup>).
							</p>
							<p id="hl0008055">
								Factors identified as potential triggers of VF
								and SCA in Brugada syndrome include some
								psychotropic medications, and anesthetic agents,
								cocaine, excessive alcohol intake, and fever (<a
									id="hl0008056"
									href="http://www.brugadadrugs.org"
									target="_blank"
									>www.brugadadrugs.org</a
								>)
								<a class="inline-reference" href="#bib873"
									>[1]</a
								>,&nbsp;<a
									class="inline-reference"
									href="#bib874"
									>[2]</a
								>. These agents should be avoided, and fever
								warrants early and aggressive measures to reduce
								temperature
								<a class="inline-reference" href="#bib875"
									>(S7.9.1.3-23)</a
								>.
							</p>
							<p id="hl0008059">
								<b>Recommendation-Specific Supportive Text</b>
							</p>
							<ul id="hl0008061">
								<li id="hl0008062">
									<span class="list-item-label">1.</span>
									<p id="hl0008064">
										The risk of major adverse cardiac events
										in asymptomatic patients without
										spontaneous type 1 electrocardiographic
										changes of Brugada syndrome ( ), or with
										only medication-induced
										electrocardiographic changes, is low
										<a
											class="inline-reference"
											href="#bib853"
											>[1]</a
										>,&nbsp;<a
											class="inline-reference"
											href="#bib854"
											>[2]</a
										>,&nbsp;<a
											class="inline-reference"
											href="#bib855"
											>[3]</a
										>,&nbsp;<a
											class="inline-reference"
											href="#bib856"
											>[4]</a
										>,&nbsp;<a
											class="inline-reference"
											href="#bib857"
											>[5]</a
										>. A positive family history of Brugada
										syndrome or SCA is not a significant
										predictor of adverse events in Brugada
										syndrome
										<a
											class="inline-reference"
											href="#bib853"
											>[1]</a
										>,&nbsp;<a
											class="inline-reference"
											href="#bib854"
											>[2]</a
										>,&nbsp;<a
											class="inline-reference"
											href="#bib856"
											>[3]</a
										>,&nbsp;<a
											class="inline-reference"
											href="#bib857"
											>[4]</a
										>. Implantation of an ICD in an
										asymptomatic patient without a
										spontaneous type 1 Brugada
										electrocardiographic has not been shown
										to confer any benefit.
									</p>
								</li>
								<li id="hl0008068">
									<span class="list-item-label">2.</span>
									<p id="hl0008070">
										Brugada syndrome is characterized by
										coved ST elevation in leads V1 or V2
										positioned in the second, third, or
										fourth intercostal space either
										spontaneously or induced by
										administration of a sodium
										channel–blocking drug in the absence of
										other causes of ST elevation
										<a
											class="inline-reference"
											href="#bib876"
											>(S7.9.1.3-24)</a
										>
										and negative T waves in the right
										precordial leads, and is associated with
										syncope or SCA due to VF, predominantly
										in young males, although it has been
										reported in all age groups. The type 1
										Brugada ECG with coved ST elevation in
										right precordial leads may be present
										spontaneously, during fever or vagotonic
										states, or after medication challenge
										with sodium channel blockers. QRS
										complex fractionation is seen in a
										minority of patients. Patients with
										spontaneous coved type ST elevation and
										a history of syncope or prior SCA are at
										the highest risk for potentially lethal
										VA. ICD implantation has been shown to
										reduce mortality in symptomatic patients
										with Brugada syndrome
										<a
											class="inline-reference"
											href="#bib877"
											>[1]</a
										>,&nbsp;<a
											class="inline-reference"
											href="#bib878"
											>[2]</a
										>.
									</p>
								</li>
								<li id="hl0008073">
									<span class="list-item-label">3.</span>
									<p id="hl0008075">
										Ablation of abnormal areas of epicardial
										late activation in the RV can suppress
										recurrent VA as shown in a small number
										of patients
										<a
											class="inline-reference"
											href="#bib860"
											>[1]</a
										>,&nbsp;<a
											class="inline-reference"
											href="#bib861"
											>[2]</a
										>,&nbsp;<a
											class="inline-reference"
											href="#bib863"
											>[3]</a
										>,&nbsp;<a
											class="inline-reference"
											href="#bib879"
											>[4]</a
										>. In these reports, the spontaneous
										type 1 Brugada pattern on ECG may be
										eliminated in &gt;75% of patients, and
										recurrences of VT/VF are markedly
										reduced
										<a
											class="inline-reference"
											href="#bib861"
											>[1]</a
										>,&nbsp;<a
											class="inline-reference"
											href="#bib862"
											>[2]</a
										>,&nbsp;<a
											class="inline-reference"
											href="#bib863"
											>[3]</a
										>. Experience and follow-up after
										ablation are limited, and an ICD for
										patients who have had syncope or SCA is
										recommended. A series of patients with
										Brugada syndrome treated with quinidine
										had no deaths during a mean follow-up of
										over 9 years, although adverse effects
										of quinidine were reported in 38% of
										patients, these authors felt that
										quinidine could be used as an
										alternative to the ICD in selected
										patients
										<a
											class="inline-reference"
											href="#bib859"
											>(S7.9.1.3-7)</a
										>.
									</p>
								</li>
								<li id="hl0008079">
									<span class="list-item-label">4.</span>
									<p id="hl0008081">
										Observational studies show that
										quinidine can suppress VF storm in
										patients with Brugada syndrome, and a
										low risk of arrhythmia was observed in a
										long-term observational study (681). No
										patient treated with quinidine
										experienced SCD. Adverse effects of
										quinidine occur in up to 37% of
										patients. Catheter ablation targeting
										the epicardial right ventricular areas
										of abnormality has also been shown to
										reduce recurrent VF episodes and
										normalize the ECG (682, 684, 685).
									</p>
								</li>
								<li id="hl0008082">
									<span class="list-item-label">5.</span>
									<p id="hl0008084">
										Administration of procainamide,
										flecainide, or ajmaline may be useful to
										provoke type 1 ST elevation in patients
										suspected to have Brugada syndrome as a
										cause of symptoms but who do not have a
										type 1 electrocardiographic pattern at
										baseline. Medication challenge should be
										terminated with the development of VA,
										marked QRS widening, or type 1 Brugada
										electrocardiographic pattern
										<a
											class="inline-reference"
											href="#bib866"
											>[1]</a
										>,&nbsp;<a
											class="inline-reference"
											href="#bib880"
											>[2]</a
										>. The use of high electrocardiographic
										electrode positioning in the second and
										third interspaces for
										electrocardiographic recording improves
										detection of a type 1 Brugada ECG
										<a
											class="inline-reference"
											href="#bib881"
											>(S7.9.1.3-29)</a
										>. Asymptomatic patients with a family
										history of Brugada syndrome may be
										offered sodium channel blocker challenge
										for diagnostic evaluation, although a
										positive test does not require chronic
										therapy due to a low risk in this
										setting
										<a
											class="inline-reference"
											href="#bib864"
											>(S7.9.1.3-12)</a
										>. In asymptomatic patients with type 1
										Brugada electrocardiographic findings,
										medication challenge does not offer
										additional diagnostic value.
									</p>
								</li>
								<li id="hl0008088">
									<span class="list-item-label">6.</span>
									<p id="hl0008090">
										Polymorphic VT/VF induced by programmed
										stimulation has been associated with an
										increased risk of VA in some patients
										with spontaneous type 1 Brugada ECG
										<a
											class="inline-reference"
											href="#bib865"
											>(S7.9.1.3-13)</a
										>. The specificity of programmed
										stimulation for assessing risk decreases
										with the inclusion of triple
										extrastimuli
										<a
											class="inline-reference"
											href="#bib858"
											>[1]</a
										>,&nbsp;<a
											class="inline-reference"
											href="#bib865"
											>[2]</a
										>. The value of programmed stimulation
										in asymptomatic patients with
										spontaneous type 1 Brugada ECGs has been
										the subject of multiple studies
										<a
											class="inline-reference"
											href="#bib853"
											>[1]</a
										>,&nbsp;<a
											class="inline-reference"
											href="#bib854"
											>[2]</a
										>,&nbsp;<a
											class="inline-reference"
											href="#bib856"
											>[3]</a
										>,&nbsp;<a
											class="inline-reference"
											href="#bib857"
											>[4]</a
										>. A report found that the prognostic
										value has decreased over time, possibly
										as patients with less severe phenotypes
										have been recognized and studied
										<a
											class="inline-reference"
											href="#bib853"
											>(S7.9.1.3-1)</a
										>. Some experts use the results of
										programmed ventricular stimulation for
										informing shared decision-making in
										consideration of the ICD. In symptomatic
										patients with Brugada syndrome,
										programmed ventricular stimulation for
										risk stratification does not add
										anything to the evaluation of the
										patients as an ICD is warranted
										<a
											class="inline-reference"
											href="#bib854"
											>[1]</a
										>,&nbsp;<a
											class="inline-reference"
											href="#bib856"
											>[2]</a
										>,&nbsp;<a
											class="inline-reference"
											href="#bib858"
											>[3]</a
										>.
									</p>
								</li>
								<li id="hl0008096">
									<span class="list-item-label">7.</span>
									<p id="hl0008098">
										The yield of genetic testing in
										phenotype positive patients is
										approximately 20% to 30% in Brugada
										syndrome
										<a
											class="inline-reference"
											href="#bib856"
											>[1]</a
										>,&nbsp;<a
											class="inline-reference"
											href="#bib868"
											>[2]</a
										>,&nbsp;<a
											class="inline-reference"
											href="#bib870"
											>[3]</a
										>,&nbsp;<a
											class="inline-reference"
											href="#bib871"
											>[4]</a
										>,&nbsp;<a
											class="inline-reference"
											href="#bib882"
											>[5]</a
										>,&nbsp;<a
											class="inline-reference"
											href="#bib883"
											>[6]</a
										>. <i>SCN5A</i> variants account for
										most of this subset of genotype positive
										Brugada syndrome. However, 2% to 10% of
										otherwise healthy individuals host a
										rare variant of <i>SCN5A</i
										><a
											class="inline-reference"
											href="#bib872"
											>[1]</a
										>,&nbsp;<a
											class="inline-reference"
											href="#bib883"
											>[2]</a
										>. A negative genetic test does not
										exclude the diagnosis of Brugada
										syndrome, which is usually based on
										electrocardiographic and clinical
										characteristics. Risk stratification is
										based on symptoms and clinical findings
										<a
											class="inline-reference"
											href="#bib884"
											>(S7.9.1.3-32)</a
										>; genotype status is not correlated
										with the risk of adverse events
										<a
											class="inline-reference"
											href="#bib857"
											>[1]</a
										>,&nbsp;<a
											class="inline-reference"
											href="#bib870"
											>[2]</a
										>,&nbsp;<a
											class="inline-reference"
											href="#bib871"
											>[3]</a
										>,&nbsp;<a
											class="inline-reference"
											href="#bib885"
											>[4]</a
										>. Identification of a pathogenetic
										mutation may help facilitate recognition
										of carrier status in family members,
										allowing for lifestyle modification and
										potential treatment.
									</p>
								</li>
								<li id="hl0008105">
									<span class="list-item-label">8.</span>
									<p id="hl0008107">
										Factors identified as potential triggers
										of VF and SCA in Brugada syndrome
										include some psychotropic medications,
										and anesthetic agents, cocaine,
										excessive alcohol intake, and fever (<a
											id="hl0008108"
											href="http://www.brugadadrugs.org"
											target="_blank"
											>www.brugadadrugs.org</a
										>)
										<a
											class="inline-reference"
											href="#bib873"
											>[1]</a
										>,&nbsp;<a
											class="inline-reference"
											href="#bib874"
											>[2]</a
										>. These agents should be avoided and
										fever warrants early and aggressive
										measures to reduce temperature
										<a
											class="inline-reference"
											href="#bib875"
											>(S7.9.1.3-23)</a
										>.
									</p>
								</li>
							</ul>
						</section>
					</section>
				</section>
			</section>
		</div>
	</body>
</html>
